Both strategies strengthen the anti-angiogenic profile of OVs and complement their lytic activity within the tumor microenvironment, counteracting the central role of VEGF-driven angiogenesis in CRC and extending beyond the effects of conventional anti-VEGF drugs already used in clinical practice [19]. The gene discussed is VEGFA; the disease is colorectal carcinoma.